Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00104-024-02228-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Neoadjuvant FOLFIRINOX chemotherapy followed by preoperative chemoradiotherapy in patients with locally advanced rectal cancer].
Chirurgie (Heidelb)
January 2025
Klinik für Allgemein‑, Viszeral‑, Gefäß‑, Transplantations- und Kinderchirurgie, Universitätsklinik Würzburg, 97080, Würzburg, Deutschland.
Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer.
Front Oncol
December 2024
Research Institute of Internal Medicine and Norwegian PSC Research Center, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.
Article Synopsis
- A study explored the link between a bacterial metabolite, indole 3-acetate (3-IAA), and chemotherapy response in non-metastatic pancreatic ductal adenocarcinoma (PDAC) patients, building on previous findings in metastatic cases.
- Researchers measured 3-IAA levels in blood from 124 patients with locally advanced or borderline resectable PDAC before they started chemotherapy, primarily FOLFIRINOX.
- The results showed no significant association between pre-treatment 3-IAA levels and overall survival, suggesting that the positive effects seen in metastatic cases may not apply to non-metastatic patients, highlighting the need for further research.
Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Portal Vein Reconstruction and Celiac Axis Resection for Pancreatic Neck-Body Cancer.
Ann Surg Oncol
December 2024
Chongqing Key Laboratory of Intelligent Medicine Engineering for Hepatopancreatobiliary Diseases, Chongqing General Hospital, Chongqing University, Chongqing, China.
Background: Laparoscopic radical antegrade modular pancreatosplenectomy combined with celiac axis resection and portal vein reconstruction is a new procedure for the treatment of pancreatic cancer. This surgical technique may offer patients with pancreatic cancer involving the portal vein and celiac axis an opportunity for radical surgical resection. We aim to evaluate the short- and long-term efficacy and describe the surgical details of this technique.
View Article and Find Full Text PDFBiochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which is Best?
Ann Surg
December 2024
Department of Surgery, Stanford University, Stanford, CA.
Objective: To examine the optimal method of assessing response to neoadjuvant therapy (NAT) in operable pancreatic ductal adenocarcinoma (PDAC) patients.
Summary Of Background Data: PDAC response to NAT is measured with biochemical, radiographic and pathologic parameters, which can often be discordant with each other.
Methods: PDAC patients undergoing resection after NAT at a single institution were retrospectively analyzed.
Pancreatic carcinoma is a prognostically unfavorable cancer disease with growing incidence and mortality, which is the 3rd most common cause of cancer-related death in developed countries. The 5-year survival rate does not exceed 11% and is the lowest across all cancer diagnoses. Only about 20-30% of patients have resectable (RPC) or borderline resectable (BRPC) disease at the time of diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!